Patent ID: 11911470
Assignee: CEDARS-SINAI MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 14:
15. A method of treating borderline resectable or locally advanced pancreatic adenocarcinoma in a subject, comprising:
administering to the subject about 750 mg of durvalumab about every 14 days or about every 28 days; and
administering to the subject radiotherapy comprising (1) image guided radiotherapy (IGRT), (2) intensity modulated radiation therapy (IMRT), (3) volumetric modulated arc therapy (VMAT), and (4) stereotactic body radiation therapy (SBRT), wherein the SBRT is administered starting on about day 8, calculated from the first day of administering durvalumab, at about 6.6 Gy per fraction about every other day for 5 fractions,
thereby treating the borderline resectable or locally advanced pancreatic adenocarcinoma in the subject.